David J Goldstein

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial
    David J Goldstein
    Eli Lilly and Company, and Department of Pharmacology and Toxicology, Indiana University Medical School, Indianapolis 46285, USA
    J Clin Psychiatry 63:225-31. 2002
  2. ncbi request reprint Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    J Psychiatr Res 36:383-90. 2002
  3. ncbi request reprint Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
    J Clin Psychiatry 63:308-15. 2002
  4. ncbi request reprint Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, Toronto, Canada
    Pain Med 7:373-85. 2006
  5. ncbi request reprint Duloxetine in the long-term treatment of major depressive disorder
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Avenue, Scarborough, Ontario, Canada M1N 2E8
    J Clin Psychiatry 64:1237-44. 2003
  6. ncbi request reprint Duloxetine in treatment of anxiety symptoms associated with depression
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, Seattle, WA, USA
    Depress Anxiety 18:53-61. 2003
  7. ncbi request reprint The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition
    Stephane Chalon
    Neuropsychopharmacology 26:698-9; author reply 700-1. 2002
  8. ncbi request reprint Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine
    David J Goldstein
    PRN Consulting, Indianapolis, IN, USA
    J Clin Psychopharmacol 24:389-99. 2004
  9. ncbi request reprint A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder
    Lesley M Arnold
    University of Cincinnati College of Medicine, Cincinnati, Ohio 45219, USA
    Arthritis Rheum 50:2974-84. 2004
  10. ncbi request reprint Duloxetine vs. placebo in patients with painful diabetic neuropathy
    David J Goldstein
    PRN Consulting and Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46285, USA
    Pain 116:109-18. 2005

Detail Information

Publications13

  1. ncbi request reprint Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial
    David J Goldstein
    Eli Lilly and Company, and Department of Pharmacology and Toxicology, Indiana University Medical School, Indianapolis 46285, USA
    J Clin Psychiatry 63:225-31. 2002
    ..Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for therapeutic efficacy and safety/tolerability in the treatment of major depression...
  2. ncbi request reprint Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    J Psychiatr Res 36:383-90. 2002
    ..There was no significant incidence of hypertension, nor any other safety issues. Duloxetine 60 mg administered once daily appears to be a safe and effective treatment for MDD...
  3. ncbi request reprint Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
    J Clin Psychiatry 63:308-15. 2002
    ..Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for efficacy and tolerability/safety in the treatment of MDD and associated physical symptoms...
  4. ncbi request reprint Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, Toronto, Canada
    Pain Med 7:373-85. 2006
    ..This study assessed the 6-month safety and tolerability of duloxetine in patients with DPNP; evaluation of efficacy was a secondary objective...
  5. ncbi request reprint Duloxetine in the long-term treatment of major depressive disorder
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Avenue, Scarborough, Ontario, Canada M1N 2E8
    J Clin Psychiatry 64:1237-44. 2003
    ..This clinical trial evaluated the long-term (1 year) safety and efficacy of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, in patients with DSM-IV major depressive disorder...
  6. ncbi request reprint Duloxetine in treatment of anxiety symptoms associated with depression
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, Seattle, WA, USA
    Depress Anxiety 18:53-61. 2003
    ..Efficacy in these three key symptom domains may in turn explain the high probabilities of remission (43-57%) observed in these studies...
  7. ncbi request reprint The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition
    Stephane Chalon
    Neuropsychopharmacology 26:698-9; author reply 700-1. 2002
  8. ncbi request reprint Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine
    David J Goldstein
    PRN Consulting, Indianapolis, IN, USA
    J Clin Psychopharmacol 24:389-99. 2004
    ..Major depressive disorder causes significant morbidity and mortality. Current therapies fail to fully treat both emotional and physical symptoms of major depressive disorder...
  9. ncbi request reprint A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder
    Lesley M Arnold
    University of Cincinnati College of Medicine, Cincinnati, Ohio 45219, USA
    Arthritis Rheum 50:2974-84. 2004
    ..To assess the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in subjects with primary fibromyalgia, with or without current major depressive disorder...
  10. ncbi request reprint Duloxetine vs. placebo in patients with painful diabetic neuropathy
    David J Goldstein
    PRN Consulting and Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46285, USA
    Pain 116:109-18. 2005
    ..Duloxetine at 60 and 120 mg/d was safe and effective in the management of diabetic peripheral neuropathic pain...
  11. ncbi request reprint A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder
    Lesley M Arnold
    Women s Health Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45219, USA
    Pain 119:5-15. 2005
    ..In conclusion, both duloxetine 60 mg QD and duloxetine 60 mg BID were effective and safe in the treatment of fibromyalgia in female patients with or without major depressive disorder...
  12. ncbi request reprint Effects of duloxetine on painful physical symptoms associated with depression
    David J Goldstein
    Department of Psychitry adn the Department of Pharmacology adn toxicology, Indiana Unibersity School of Medicine, Indianapolis, USA
    Psychosomatics 45:17-28. 2004
    ..Compared with placebo, duloxetine was associated with significant reduction in pain severity. The authors concluded that duloxetine reduces the painful physical symptoms of depression...
  13. ncbi request reprint Adverse pregnancy outcomes with SSRIs
    David J Goldstein
    Am J Obstet Gynecol 196:e25; author reply e25. 2007